Braveheart Bio Inc(BRVE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:00 PM ET (Korea 10/23 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 76.55% | Shs Outstand | 90.0M | Perf Week | 9.87% |
| Market Cap | 1.93B | Forward P/E | - | EPS next Y | - | Insider Trans | 14.7% | Shs Float | 21.1M | Perf Month | 0.09% |
| Enterprise Value | 2.03B | PEG | - | EPS next Q | -0.44 | Inst Own | - | Short Float | 19.56% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 15.82% | Short Ratio | 8.04 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 4.13M | Perf YTD | -28.87% |
| Book/sh | -1.07 | P/C | 15.75 | EPS past 3/5Y | - | ROE | - | 52W High | -32.88% ($32.00) | Perf Year | - |
| Cash/sh | 1.36 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 20.27% ($17.86) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 7.61% 9.49% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 13.63 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 49.12 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 13.63 | Sales Q/Q | - | SMA20 | 6.07% ($20.25) | Beta | - | Target Price | $45.25 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/8 | SMA50 | -11.25% ($24.2) | Rel Volume | 0.3 | Prev Close | $21.04 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | -193.45% - | SMA200 | -12.4% ($24.52) | Avg Volume(3M) | 0.51M | Price | $21.48 |
| IPO | 2026/8/6 | Option/Short | No/Yes | Trades | 2453 | Volume | 156,504 | Change | 2.09% |
A clinical-stage biotech company developing treatments for severe cardiovascular diseases, including hypertrophic cardiomyopathy. Founded in 2024 and headquartered in San Francisco, the company is focused on developing an oral cardiac myosin inhibitor as its lead asset, which works by suppressing excessive contraction of the heart muscle. It is a recently formed company that has secured its funding base through a new listing on NASDAQ.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
Traded less than usual. That is 30% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Shareholder Composition Guide
Tap to view numbers
It ranks #99 of 594 in the industry
Based on market cap of $2B.
ADRX#98 ADARx Pharmaceuticals Inc $2B PER - BRVE#99 Braveheart Bio Inc $2B PER - 
XNCR#100 Xencor Inc $2B PER - 
SRPT#101 Sarepta Therapeutics Inc $2B PER - 
SEPN#102 Septerna Inc $2B PER - 
FAQ
What kind of company is BRVE?
BRVE belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BRVE?
The market cap of BRVE is approximately $1.9B, ranking 2,080 within its sector.
What is the 52-week high and low for BRVE?
BRVE has recorded a 52-week high of $32.00 and a low of $17.86.
